SCHEMBL2385753

SCHEMBL2385753

COc1cccc2c1c(O)c(C(=O)NC(C)C(=O)O)c(=O)n2C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.49
BRPF1 P55201 2/20 0.44
TSHR P16473 1/20 0.44
HIF1A Q16665 2/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAP3K5 Q99683 1/20 0.41
POLB P06746 2/20 0.40
EGFR P00533 2/20 0.39
SRC P12931 2/20 0.39
PABPC1 P11940 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385748 1.00 HDAC4 (0.51) HDAC4L3MBTL1BRPF1TSHRHIF1A
SCHEMBL2383516 0.91 HDAC4 (0.53) HDAC4L3MBTL1BRPF1TSHRHIF1A
SCHEMBL12254511 0.91 HDAC4 (0.51) HDAC4L3MBTL1BRPF1TSHRHIF1A
SCHEMBL2383515 0.91 HDAC4 (0.53) HDAC4L3MBTL1BRPF1TSHRHIF1A
SCHEMBL2384050 0.85 L3MBTL1 (0.52) HDAC4L3MBTL1TSHRKDM4EALDH1A1
SCHEMBL2384054 0.85 L3MBTL1 (0.52) HDAC4L3MBTL1TSHRKDM4EALDH1A1
SCHEMBL2384168 0.84 L3MBTL1 (0.51) L3MBTL1HIF1AKDM4EALDH1A1HTT
SCHEMBL2384170 0.84 L3MBTL1 (0.51) L3MBTL1HIF1AKDM4EALDH1A1HTT
SCHEMBL2382505 0.84 L3MBTL1 (0.51) L3MBTL1HIF1AKDM4EALDH1A1HTT
SCHEMBL2382482 0.84 L3MBTL1 (0.51) HDAC4L3MBTL1KDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP claimed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 HDAC4 821/4885L3MBTL1 4035/4885BRPF1 3229/4885
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 HDAC4 743/4885L3MBTL1 4024/4885BRPF1 2855/4885
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof EGLN3, HIF1AN, EGLN2 HDAC4 743/4885L3MBTL1 4024/4885BRPF1 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.